Page last updated: 2024-10-28

go 6976 and Granulocytic Leukemia

go 6976 has been researched along with Granulocytic Leukemia in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Human myelogenous leukemia K562 cells were induced to undergo megakaryocytic differentiation by long-term treatment with phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA)."1.34Involvement of nPKC-MAPK pathway in the decrease of nucleophosmin/B23 during megakaryocytic differentiation of human myelogenous leukemia K562 cells. ( Chou, CC; Hsu, CY; Yung, BY, 2007)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Grandage, VL1
Everington, T1
Linch, DC1
Khwaja, A1
Chou, CC1
Yung, BY1
Hsu, CY1

Other Studies

2 other studies available for go 6976 and Granulocytic Leukemia

ArticleYear
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
    British journal of haematology, 2006, Volume: 135, Issue:3

    Topics: Acute Disease; Carbazoles; Cell Division; Cell Line, Tumor; Cell Survival; Cytokines; Enzyme Inhibit

2006
Involvement of nPKC-MAPK pathway in the decrease of nucleophosmin/B23 during megakaryocytic differentiation of human myelogenous leukemia K562 cells.
    Life sciences, 2007, May-08, Volume: 80, Issue:22

    Topics: Carbazoles; Cell Differentiation; Cell Line, Tumor; Humans; Indoles; K562 Cells; Leukemia, Myeloid;

2007